Amgen's two top executives are stepping down
Amgen announced that Sean E. Harper, executive vice president of research and development, and Anthony C. Hooper, executive vice president of global commercial operations, are leaving the company.
Harper has served in the biopharmaceutical industry for more than 21 years, including the past 16 years with Amgen.
David M. Reese, currently senior vice president of translational sciences and oncology at Amgen, has been appointed as executive vice president of research and development, effective today.
Reese will report to Robert A. Bradway, chairman and CEO. Harper will remain at Amgen for a period of time to facilitate the transition to Reese.
Murdo Gordon, chief commercial officer at Bristol-Myers Squibb, has been named as executive vice president of global commercial operations, effective Sept. 3. Gordon will report to Bradway. Hooper also will remain at Amgen during the transition.
"I would like to thank both Sean and Tony for the important contributions they have made to Amgen, each bringing their own vital experiences and skills," Bradway said. "They leave the company having established strong foundations within research and development and global commercial operations for the future. It is a testament to their leadership and accomplishments that they have attracted such exceptional talent to succeed them."
"I am looking forward to having Dave and Murdo join us in their new leadership roles," Bradway said. "With their deep combined expertise, they will add meaningfully to helping advance Amgen's mission of serving patients."
Harper has served in the biopharmaceutical industry for more than 21 years, including the past 16 years with Amgen.
David M. Reese, currently senior vice president of translational sciences and oncology at Amgen, has been appointed as executive vice president of research and development, effective today.
Reese will report to Robert A. Bradway, chairman and CEO. Harper will remain at Amgen for a period of time to facilitate the transition to Reese.
Murdo Gordon, chief commercial officer at Bristol-Myers Squibb, has been named as executive vice president of global commercial operations, effective Sept. 3. Gordon will report to Bradway. Hooper also will remain at Amgen during the transition.
"I would like to thank both Sean and Tony for the important contributions they have made to Amgen, each bringing their own vital experiences and skills," Bradway said. "They leave the company having established strong foundations within research and development and global commercial operations for the future. It is a testament to their leadership and accomplishments that they have attracted such exceptional talent to succeed them."
"I am looking forward to having Dave and Murdo join us in their new leadership roles," Bradway said. "With their deep combined expertise, they will add meaningfully to helping advance Amgen's mission of serving patients."